文献速递类风湿关节炎系统性红斑狼疮

肿瘤坏死因子α抑制剂治疗Rhupus的长期疗效与安全性:一项15例患者的开放标签研究

Long-term efficacy and safety of antitumour necrosis factor alpha treatment in rhupus: an open-label study of 15 patients.
PubMed 文献 · RMD Open · 2017-12-29

这项开放标签研究纳入15例传统改善病情抗风湿药治疗后DAS 28仍大于3.2的Rhupus患者,12例接受依那西普、3例接受阿达木单抗治疗。DAS 28与SLEDAI在3个月时显著下降并持续至60个月,泼尼松剂量在6个月后显著降低,严重感染率为每100患者年3.0例。

要点

  • 15例Rhupus患者中12例用依那西普、3例用阿达木单抗,DAS 28与SLEDAI在3个月时显著下降并持续至60个月。
  • 泼尼松中位剂量从基线15 mg/天降至6个月后的5 mg/天,随访期间持续低于基线。
  • 严重感染率为每100患者年3.0例,耐受性可接受。

核心结论

  • 这项先导研究提示,抗TNF-α对难治性关节炎的Rhupus患者有效,且安全性可接受。

研究设计与样本

  • 开放标签研究纳入15例Rhupus患者,这些患者尽管使用传统改善病情抗风湿药,DAS 28仍大于3.2。
  • 患者在3、6、12、24和60个月时接受SLEDAI和DAS 28监测,统计分析采用贝叶斯方法,Prob大于97.5%视为显著。

主要发现

  • 12例患者接受依那西普治疗,中位疗程62.5个月(范围6-112个月);3例患者接受阿达木单抗治疗36.0个月(范围4-52个月)。
  • 基线时DAS 28中位数为5.94(4.83-8.09),SLEDAI中位数为6(4-8)。
  • 3个月时DAS 28降至3.70(1.80-6.42)、SLEDAI降至4(0-6),两者Prob均大于99.9%。
  • 上述变化在6、12、24和60个月时持续存在,Prob均大于99.9%。
  • 泼尼松中位剂量从基线15(5-35)mg/天降至6个月后的5(0-20)mg/天,并在整个随访期间持续低于基线,Prob均大于99.9%。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The efficacy of antitumour necrosis factor alpha (anti-TNF-α) treatment is well recognised in rheumatoid arthritis (RA) but remains controversial in systemic lupus erythematosus (SLE). Therefore, the role of anti-TNF-α treatment in 'Rhupus', a disease sharing features of RA and SLE, is still debated. OBJECTIVE: To evaluate the efficacy and tolerance of anti-TNF-α in patients with rhupus. METHODS: Fifteen patients with rhupus with Disease Activity Score 28 (DAS 28) >3.2 despite conventional disease-modifying anti-rheumatic drugs were included in an open-label study. Patients were monitored at months (M) 3, 6, 12, 24 and 60 with SLE Disease Activity Index (SLEDAI) and DAS 28. Statistical analyses were performed using Bayesian methods and Prob >97.5% was considered significant. RESULTS: Twelve patients were treated with etanercept for a median duration of 62.5 (range: 6-112) months and three patients by adalimumab during 36.0 (range: 4-52) months. At baseline, median DAS 28 and SLEDAI were 5.94 (4.83-8.09) and 6 (4-8), respectively. DAS 28 and SLEDAI decreased significantly after 3 months, respectively, to 3.70 (1.80-6.42) and 4 (0-6) (Prob >99.9%, for both). These changes persisted at M6, M12, M24 and M60 (Prob >99.9%, for all). Median prednisone dose decreased significantly from 15 (5-35) mg/day to 5 (0-20) mg/day after 6 months and over the follow-up (Prob >99.9%, for all). Tolerance was acceptable, with a severe infection rate of 3.0 per 100 patient-years. CONCLUSION: This pilot study suggests that anti-TNF-α is effective in patients with rhupus with refractive arthritis and has an acceptable safety profile.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Danion F, Sparsa L, Arnaud L, et al. Long-term efficacy and safety of antitumour necrosis factor alpha treatment in rhupus: an open-label study of 15 patients. RMD Open. 2017. PMID: 29435362. doi:10.1136/rmdopen-2017-000555

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。